Trial Profile

Phase 2 Study of Zelenectide Pevedotin in Participants With NECTIN4 Amplified Advanced Breast Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zelenectide pevedotin (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms Duravelo-3
Sponsors Bicycle Therapeutics

Most Recent Events

17 Mar 2026 Status changed from recruiting to discontinued due to strategic reprioritization, according to a Bicycle Therapeutics media release. Further enrollment for these trials will be closed, and patients already enrolled will complete their course of treatment.
12 Jan 2026 According to a Bicycle Therapeutics media release, initial data from this trial expected to be presented at a scientific conference in the second half of 2026.
07 Mar 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com